BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, has been ...
Therapies from Johnson & Johnson and Takeda Pharmaceutical have validated a particular rare genetic mutation as a viable drug target for treating lung cancer. Scorpion Therapeutics aims to best those ...
SAN ANTONIO, Texas, Dec. 20, 2022 /PRNewswire/ -- Scorpion Biological Services today announced it has changed its name to Scorpius BioManufacturing reflecting the company's recently expanded ...
MANHATTAN, Kan., April 26, 2022 /PRNewswire/ -- Biopharmaceutical contract development and manufacturing organization (CDMO) Scorpion Biological Services (Scorpion) today announced a planned ...
In less than a year, Scorpion Therapeutics Inc. has raised about $270 million and just closed on an oversubscribed series B financing that climbed to $162 million. The new financing quickly follows ...
Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR ...
Scorpion Biological Services changed its name to Scorpius BioManufacturing to reflect its recently expanded manufacturing capabilities and the opening of its new bioprocessing facility in San Antonio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback